SOLARAZE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Solaraze, and when can generic versions of Solaraze launch?
Solaraze is a drug marketed by Fougera Pharms and is included in one NDA.
The generic ingredient in SOLARAZE is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Solaraze
A generic version of SOLARAZE was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SOLARAZE?
- What are the global sales for SOLARAZE?
- What is Average Wholesale Price for SOLARAZE?
Summary for SOLARAZE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 121 |
Clinical Trials: | 11 |
Patent Applications: | 3,921 |
What excipients (inactive ingredients) are in SOLARAZE? | SOLARAZE excipients list |
DailyMed Link: | SOLARAZE at DailyMed |
Recent Clinical Trials for SOLARAZE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Infectopharm Arzneimittel GmbH | Phase 3 |
Gesellschaft für Therapieforschung mbH | Phase 3 |
Encube Ethicals Pvt. Ltd. | Phase 3 |
Paragraph IV (Patent) Challenges for SOLARAZE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SOLARAZE | Topical Gel | diclofenac sodium | 3% | 021005 | 1 | 2009-12-16 |
US Patents and Regulatory Information for SOLARAZE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fougera Pharms | SOLARAZE | diclofenac sodium | GEL;TOPICAL | 021005-001 | Oct 16, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SOLARAZE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Fougera Pharms | SOLARAZE | diclofenac sodium | GEL;TOPICAL | 021005-001 | Oct 16, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Fougera Pharms | SOLARAZE | diclofenac sodium | GEL;TOPICAL | 021005-001 | Oct 16, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Fougera Pharms | SOLARAZE | diclofenac sodium | GEL;TOPICAL | 021005-001 | Oct 16, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Fougera Pharms | SOLARAZE | diclofenac sodium | GEL;TOPICAL | 021005-001 | Oct 16, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SOLARAZE
See the table below for patents covering SOLARAZE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 308201 | ⤷ Sign Up | |
Slovakia | 11193 | FORMULATIONS CONTAINING HYALURONIC ACID | ⤷ Sign Up |
Norway | 312939 | ⤷ Sign Up | |
Hungary | 225963 | PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BASAL CELL CARCINOMA AND ACTINIC KERATOSES | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |